Skip to content
Screener

BioCryst Pharmaceuticals BCRX Q4 2025 Annual earnings

Reported February 26, 2026 · Before market open

Revenue$406.6MBeat by $255.2M
EPS$1.12Beat by $1.05
Revenue estimate$151.3M
EPS estimate$0.07

Next report

Nov 2, 2026 (in a month)
Revenue estimate$165.7M
EPS estimate$0.10

Financials

Q4 2025

Income statement

See full
Revenue$406.6M+209%
Gross profit$397.0M+217%
Operating income$260.4M+5,876%
Net income$245.8M+1,018%
EPS (diluted)$1.13+969%

Balance sheet

See full
Cash & equivalents$91.3M-14.1%
Total debt$13.0M-96.1%
Total equity-$119.2M+75.0%
Total assets$514.2M+4.8%

Cash flow

See full
Operating cash flow$292.0M+5,701%
CapEx$802.0K+18.8%
Free cash flow$291.2M+5,045%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.64B+5.5%
Enterprise value$1.57B-12.1%
P/E6.2×—
P/S1.9×-1.6×

Profitability

See full
Gross margin97.8%+0.5pp
Operating margin39%+38.4pp
Net margin30.2%+21.6pp
FCF margin39.4%—

Returns & leverage

See full
Current ratio2.1×-0.6×

Segments

By segment

See full
Reportable Segment$406.6M+209%

FAQ

When did BioCryst Pharmaceuticals report Q4 2025 earnings?
BioCryst Pharmaceuticals (BCRX) reported Q4 2025 earnings on February 26, 2026 before market open.
What were BioCryst Pharmaceuticals's Q4 2025 revenue and EPS?
BioCryst Pharmaceuticals reported revenue of $406.6M and eps of $1.12 for Q4 2025.
Did BioCryst Pharmaceuticals beat estimates in Q4 2025?
Revenue beat the consensus estimate of $151.3M by $255.2M. EPS beat the consensus estimate of $0.07 by $1.05.
How did BioCryst Pharmaceuticals's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 209.1% from $131.5M a year earlier.
Where can I find BioCryst Pharmaceuticals's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001171843-26-001119) and the 10-K periodic report (0001628280-26-012240) directly on SEC EDGAR. The filing index links above go to sec.gov.